“We are incredibly excited to welcome Vanessa to our management crew at an critical time in the development of our firm to carry gene remedy to daily life,” reported Jonathan Thon, CEO and Founder of STRM.BIO. “Vanessa delivers an fantastic track record of achievements in small business enhancement and value creation to STRM.BIO as we define and execute on our partnering approach to provide the following generations of mobile and gene therapies. She will be instrumental in ongoing discussions with likely associates as very well as discovering new alternatives.”
“The prospective of STRM’s system to ultimately make gene therapy available is transformative! I’m thrilled to be a part of STRM.BIO and assistance speed up the software of STRM’s EV system to split by the limits of present day gene treatment systems,” mentioned Mrs. Salazar. “STRM.BIO has revealed a differentiated capacity to goal hematopoietic stem cells in vivo, tunably load, and supply multiplexed DNA, RNA, and protein cargo, and support repeat dosing—finally opening the door to in vivo gene delivery. I look ahead to working carefully with this outstanding staff to generate new possibilities for enlargement of our platform and advance our mission of democratizing gene therapy.”
Mrs. Salazar has been concerned in corporate strategic arranging and offer structuring for a selection of transactions like in- and out-licensing, divestitures, and co-improvement promotions. She has led and transacted business deals with an aggregate price of above $2.5B, managed a portfolio of much more than 20 alliances across a assortment of exceptional diseases, metabolic, oncology, and immunology indications and a number of modalities which include compact molecule, biologics, and gene treatment. Most a short while ago, she was Executive Director of Company Progress and Strategic Partnerships at Passage Bio. Prior to her time at Passage, she served as the Company Progress Direct at Spark Therapeutics. She began her occupation in organization enhancement for the duration of a sixteen-calendar year tenure at GlaxoSmithKline. She is a graduate of Rutgers University.
Based in Boston, MA, STRM.BIO is a pre-medical, VC-backed biotechnology firm that is leveraging extracellular vesicles (EVs) to produce gene therapy in a superior way: less difficult, safer, simple. Our do the job will open the door to the future of medicine for patients residing with scarce conditions globally. STRM.BIO is dedicated to bringing gene treatment to everyday living. Be sure to pay a visit to strm.bio to fulfill our expanding staff of partners and collaborators and stay up to date on our progress.